160 related articles for article (PubMed ID: 34439125)
1. ELOVL5-Mediated Long Chain Fatty Acid Elongation Contributes to Enzalutamide Resistance of Prostate Cancer.
Xu H; Li S; Sun Y; Xu L; Hong X; Wang Z; Hu H
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439125
[TBL] [Abstract][Full Text] [Related]
2. Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals.
Dang Q; Li L; Xie H; He D; Chen J; Song W; Chang LS; Chang HC; Yeh S; Chang C
Mol Oncol; 2015 Aug; 9(7):1241-51. PubMed ID: 25817444
[TBL] [Abstract][Full Text] [Related]
3. ELOVL5-mediated fatty acid elongation promotes cellular proliferation and invasion in renal cell carcinoma.
Nitta S; Kandori S; Tanaka K; Sakka S; Siga M; Nagumo Y; Negoro H; Kojima T; Mathis BJ; Shimazui T; Miyamoto T; Matsuzaka T; Shimano H; Nishiyama H
Cancer Sci; 2022 Aug; 113(8):2738-2752. PubMed ID: 35670054
[TBL] [Abstract][Full Text] [Related]
4. ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
Centenera MM; Scott JS; Machiels J; Nassar ZD; Miller DC; Zinonos I; Dehairs J; Burvenich IJG; Zadra G; Chetta PM; Bango C; Evergren E; Ryan NK; Gillis JL; Mah CY; Tieu T; Hanson AR; Carelli R; Bloch K; Panagopoulos V; Waelkens E; Derua R; Williams ED; Evdokiou A; Cifuentes-Rius A; Voelcker NH; Mills IG; Tilley WD; Scott AM; Loda M; Selth LA; Swinnen JV; Butler LM
Cancer Res; 2021 Apr; 81(7):1704-1718. PubMed ID: 33547161
[TBL] [Abstract][Full Text] [Related]
5. Enzalutamide-Induced Upregulation of PCAT6 Promotes Prostate Cancer Neuroendocrine Differentiation by Regulating miR-326/HNRNPA2B1 Axis.
Liu B; Jiang HY; Yuan T; Luo J; Zhou WD; Jiang QQ; Wu D
Front Oncol; 2021; 11():650054. PubMed ID: 34277403
[TBL] [Abstract][Full Text] [Related]
6. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
[TBL] [Abstract][Full Text] [Related]
7. Modulation of de Novo Lipogenesis Improves Response to Enzalutamide Treatment in Prostate Cancer.
Lounis MA; Péant B; Leclerc-Desaulniers K; Ganguli D; Daneault C; Ruiz M; Zoubeidi A; Mes-Masson AM; Saad F
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33187317
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of protein kinase C/Twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer.
Shiota M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Song Y; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Clin Cancer Res; 2014 Feb; 20(4):951-61. PubMed ID: 24352647
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
10. Elevating SOX2 in prostate tumor cells upregulates expression of neuroendocrine genes, but does not reduce the inhibitory effects of enzalutamide.
Metz EP; Wilder PJ; Dong J; Datta K; Rizzino A
J Cell Physiol; 2020 Apr; 235(4):3731-3740. PubMed ID: 31587305
[TBL] [Abstract][Full Text] [Related]
11. The circRAB3IP Mediated by eIF4A3 and LEF1 Contributes to Enzalutamide Resistance in Prostate Cancer by Targeting miR-133a-3p/miR-133b/SGK1 Pathway.
Chen D; Wang Y; Yang F; Keranmu A; Zhao Q; Wu L; Han S; Xing N
Front Oncol; 2021; 11():752573. PubMed ID: 34868959
[TBL] [Abstract][Full Text] [Related]
12. Polyunsaturated fatty acids synthesized by freshwater fish: A new insight to the roles of elovl2 and elovl5 in vivo.
Sun S; Ren T; Li X; Cao X; Gao J
Biochem Biophys Res Commun; 2020 Nov; 532(3):414-419. PubMed ID: 32883522
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X
J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587
[TBL] [Abstract][Full Text] [Related]
14. miR-146a is involved in the regulation of vertebrate LC-PUFA biosynthesis by targeting elovl5 as demonstrated in rabbitfish Siganus canaliculatus.
Chen C; Zhang J; Zhang M; You C; Liu Y; Wang S; Li Y
Gene; 2018 Nov; 676():306-314. PubMed ID: 30145362
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
Chen X; Liu J; Cheng L; Li C; Zhang Z; Bai Y; Wang R; Han T; Huang C; Kong Y; Feng F; Liu X
Prostate; 2020 Feb; 80(3):256-266. PubMed ID: 31856338
[TBL] [Abstract][Full Text] [Related]
16. Polyunsaturated fatty acid elongation and desaturation in activated human T-cells: ELOVL5 is the key elongase.
Robichaud PP; Munganyiki JE; Boilard E; Surette ME
J Lipid Res; 2018 Dec; 59(12):2383-2396. PubMed ID: 30293059
[TBL] [Abstract][Full Text] [Related]
17. Fatty acid elongase 5 (ELOVL5) alters the synthesis of long-chain unsaturated fatty acids in goat mammary epithelial cells.
Shi HB; Du Y; Zhang CH; Sun C; He YL; Wu YH; Liu JX; Luo J; Loor JJ
J Dairy Sci; 2018 May; 101(5):4586-4594. PubMed ID: 29454701
[TBL] [Abstract][Full Text] [Related]
18. ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis.
Niu Y; Guo C; Wen S; Tian J; Luo J; Wang K; Tian H; Yeh S; Chang C
Cancer Lett; 2018 Dec; 439():47-55. PubMed ID: 30227222
[TBL] [Abstract][Full Text] [Related]
19. Therapy-induced lipid uptake and remodeling underpin ferroptosis hypersensitivity in prostate cancer.
Tousignant KD; Rockstroh A; Poad BLJ; Talebi A; Young RSE; Taherian Fard A; Gupta R; Zang T; Wang C; Lehman ML; Swinnen JV; Blanksby SJ; Nelson CC; Sadowski MC
Cancer Metab; 2020; 8():11. PubMed ID: 32577235
[TBL] [Abstract][Full Text] [Related]
20. Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells.
Wen S; Niu Y; Lee SO; Yeh S; Shang Z; Gao H; Li Y; Chou F; Chang C
Mol Carcinog; 2016 Dec; 55(12):2278-2290. PubMed ID: 26894509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
